We seek to understand the relationship between two classical AD biomarkers, amyloid-β1−42 (Aβ1−42) and total-tau (t-tau), and define their trajectories across disease development, as defined by disease onset at diagnosis of mild cognitive impairment (MCI). Here, MAPT is linked to Alzheimer disease.